MCL1 Rekombinanter Antikörper

MCL1 Rekombinant Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

CloneNo.

5P13

Kat-Nr. : 82695-4-RR

Synonyme

EAT, Mcl 1, Mcl 1l, Mcl 1s Delta TM, MCL1, mcl1/EAT, MCL1L, MCL1S, TM

---

Galerie der Validierungsdaten

• 

  WB analysis using 82695-4-RR

  Various lysates were subjected to SDS PAGE followed by western blot with 82695-4-RR (MCL1 antibody) at dilution of 1:5000 incubated at room temperature for 1.5 hours.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: HeLa-Zellen, HEK-293-Zellen, Jurkat-Zellen, MDA-MB-231-Zellen, Raji-Zellen

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:2000-1:10000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

82695-4-RR bindet in WB, ELISA MCL1 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: MCL1 fusion protein Ag10397
• Vollständiger Name: myeloid cell leukemia sequence 1 (BCL2-related)
• Berechnetes Molekulargewicht: 350 aa, 37 kDa
• Beobachtetes Molekulargewicht: 40 kDa
• GenBank-Zugangsnummer: BC107735
• Gene symbol: MCL1
• Gene ID (NCBI): 4170
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-A-Reinigung
• Lagerungspuffer: PBS mit 0.02% Natriumazid und 50% Glycerin pH 7.3.
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

MCL-1 is an anti-apoptotic member of the Bcl-2 family originally isolated from the ML-1 human myeloid leukemia cell line. Similar to BCL2 and BCL2L1, MCL1 can interact with BAX and/or BAK1 to inhibit mitochondria-mediated apoptosis. Mcl-1 is critical for the proliferation and survival of myeloma cells in vitro, and overexpression of Mcl-1 protein in myeloma cells is associated with relapse and short event-free survival in multiple myeloma patients. Recent studies show that MCL-1 is upregulated in numerous haematological and solid tumor malignancies. Therefore, MCL-1 has been suggested as a potential new therapeutic target. MCL-1 can be alternatively spliced into a long form (MCL-1L, 40 kDa) or a short form (MCL-1S, 30 kDa). (PMID: 15467463, PMID: 15147382)